Clinical trial NCT04546633: Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
Official title: A Phase 2 Interventional, Multicenter, Randomized, Open-label Study in Three Age-descending Cohorts to Evaluate Efficacy, Safety and Tolerability of KAF156 and Lumefantrine-SDF Combination in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in a Pediatric Population
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Uncomplicated Plasmodium Falciparum Malaria
Keywords: Plasmodium falciparum malaria
KAF156
Lumefantrine Solid Dispersion Formulation
LUM-SDF
children
Lead sponsor: Novartis
Sponsor class: INDUSTRY
Collaborators: name: European and Developing Countries Clinical Trials Partnership (EDCTP)
First posted: 2020-09-14
Enrollment: 295
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a multicenter, open-label, randomized study in adolescents and children with confirmed uncomplicated P. falciparum malaria.

This study will first explore the effect of food on lumefantrine and KAF156 PK in a Run-in Cohort of patients 12 to \< 18 years old with malaria caused by P. falciparum, before younger patients are assessed. Then, efficacy, safety and tolerability of the combination of KAF156 and LUM-SDF will be evaluated in younger patients, first in Cohort 1 of patients 2 to \< 12 years old and then in Cohort 2 of patients 6 months to \< 2 years old.

Randomization is stratified by country for patients in the Run-in cohort, by age group (6 years to \<12 and 2 to \<6 years) and country in Cohort 1 and by country in Cohort 2.
Primary purpose: TREATMENT

Brief summary: This study aims to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to \< 18 years of age) with uncomplicated P. falciparum malaria. There is an unmet medical need for anti-malarial treatment with a new mechanism of action to reduce the probability of developing resistance.

Detailed description: This Phase 2 study aims to evaluate the efficacy, safety and tolerability of the investigational drug KAF156 and a Solid Dispersion Formulation of lumefantrine (LUM-SDF) when administered in combination in pediatric patients 6 months to \< 18 years of age with uncomplicated Plasmodium falciparum malaria. In addition, pharmacokinetics (PK) of the drug combination will also be evaluated.

There will be three age-descending cohorts: Run-in Cohort, Cohort 1 and Cohort 2.

It is important to understand the impact of food on exposure. In adult healthy volunteers, LUM-SDF alone has shown a food effect whereas KAF156 does not have a food effect. This new study will first explore the effect of food on lumefantrine and KAF156 PK in malaria patients 12 to \< 18 years old with malaria caused by P. falciparum before younger patients are assessed.

Then, efficacy, safety and tolerability of the combination of KAF156 and LUM-SDF will be evaluated in younger patients, first in Cohort 1 of patients 2 to \< 12 years old and then in Cohort 2 of patients 6 months to \< 2 years old.

Eligibility criteria: Inclusion Criteria:

1. In run-in cohort: Male and female patients 12 to \< 18 years of age, with a body weight

   * 35.0 kg In Cohort 1: Male and female patients 2 to \< 12 years of age, with a body weight ≥ 10.0 kg In Cohort 2: Male and female patients 6 months to \< 2 years of age, with a body weight
   * 5.0 kg
2. Microscopic confirmation of P. falciparum by Giemsa-stained thick and thin films
3. P. falciparum parasitemia of ≥ 1,000 and ≤ 150,000 parasites/μL at the time of prescreening for the Run-in Cohort; and P. falciparum parasitemia of ≥ 1,500 and ≤ 150,000 parasites/μL at the time of pre-screening for Cohorts 1 and 2
4. Axillary temperature ≥ 37.5 ºC or oral/tympanic/rectal temperature ≥ 38.0 ºC; or history of fever during the previous 24 hours (at least documented verbally)
5. Written informed consent has been obtained from parent / legal guardian before any assessment is performed. If the parent/legal guardian is unable to read and write, then a witnessed consent according to local ethical standards is permitted. Patients who are capable of providing assent, must provide assent with parental/legal guardian consent or as per local ethical guidelines
6. The patient and his/her parent/legal guardian is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions and is likely to complete the study as planned

Exclusion Criteria:

1. Mixed Plasmodium infections as per light microscopy results
2. Signs and symptoms of severe malaria according to WHO 2015 (see Section 16.4)
3. Significant, non-plasmodial co-infections including tuberculosis
4. Patients with concurrent febrile illnesses (e.g., typhoid fever, known or suspected COVID19)
5. Known relevant liver disease e.g. chronic hepatitis, cirrhosis, compensated or decompensated, history of hepatitis B or C, hepatitis B or A vaccination in last 3 months, known gallbladder or bile duct disease, acute or chronic pancreatitis
6. Major congenital defects
7. Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection or family history of congenital or hereditary immunodeficiency
8. Immunosuppressive therapy (steroids, immune modulators or immune suppressors) within 3 months prior to recruitment. (For corticosteroids, this will mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are allowed)
9. Repeated vomiting (defined as more than 3 times in the 24 hours prior to inclusion in the study) or severe diarrhea (defined as more than 3 watery stools in the 24 hours prior to inclusion in the study)
10. Active duodenal ulcer, ulcerative colitis, Crohn's disease, chronic (i.e., \> 2 weeks) use of non-steroidal anti-inflammatory drugs (NSAIDs)
11. Clinically relevant abnormalities of electrolyte balance which require correction, e.g., hypokalemia, hypocalcemia or hypomagnesemia
12. Anemia (hemoglobin level \<7 g/dL)
13. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs (e.g., HIV patients on ART therapy or TB patients on treatment), or which may jeopardize the patient in case of participation in the study. The investigator should make this determination in consideration of the patient's medical history and/or clinical or laboratory evidence of any of the following:

    * AST/ALT \> 3 x the upper limit of normal range (ULN), regardless of the level of total bilirubin
    * AST/ALT \> 1.5 and ≤ 2 x ULN and total bilirubin is \> ULN Total bilirubin \> 2 x ULN regardless of the level of AST/ALT
14. Resting QT interval corrected by Fridericia's formula (QTcF) \> 450 ms at screening
15. Creatinine \> 2 x ULN in the absence of dehydration. In case of dehydration, creatinine should be \< 2 x ULN after oral/parenteral rehydration
16. Any severe disease condition which might prohibit participation in this study
17. Known chronic underlying disease such as sickle cell disease, and severe cardiac, renal, or hepatic impairment
18. Known active or uncontrolled thyroid disease
19. Inability to swallow oral medication (in tablet and/or liquid form)
20. Patients with prior antimalarial therapy or antibiotics with antimalarial activity within minimum of their five (5) plasma half-lives (or within 4 weeks of screening if half-life is unknown)
21. Use of other investigational drugs within 30 days of dosing or until the expected pharmacodynamic effect has returned to baseline, whichever is longer
22. Patients taking medications prohibited by the protocol
23. Previous participation in any malaria vaccine study or received malaria vaccine in any other circumstance within 3 months of dosing
24. History or family history of long QT syndrome or sudden cardiac death, or any other clinical condition known to prolong the QTc interval, such as history of symptomatic cardiac arrhythmias, clinically relevant bradycardia or severe heart disease
25. Use of agents known to prolong the QT interval unless it can be permanently discontinued for the duration of study
26. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes

    For the Run-in Cohort only:
27. Pregnant or nursing (lactating) patients
28. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of contraception during dosing of investigational drug. Basic contraception methods include:

    * Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    * Male sterilization (at least 6 m prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient
    * Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps).

    Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking investigational drug. Women are considered not of child bearing potential if they have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

    For Cohorts 1 and 2 only:
29. Patients of child bearing potential, defined as all girls post first menarche (except for Run-in Cohort)

Primary outcomes:
measure: PCR-corrected adequate clinical and parasitological response (ACPR) at Day 29 (i.e., 28 days post-dose) (Cohorts 1 and 2 pooled).
timeFrame: Day 29
Secondary outcomes:
measure: Percentage of Participants with Polymerase Chain Reaction (PCR)-corrected and uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 15 and 43
timeFrame: Day 15, Day 43
measure: Percentage of Participants with Polymerase Chain Reaction (PCR)-corrected and uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 (Run-in Cohort)
timeFrame: Day 29
measure: Time to parasite clearance (PCT)
timeFrame: up to 43 days
measure: Time to fever clearance (FCT)
timeFrame: up to 43 days
measure: Proportion of patients with Early Treatment Failure (ETF)
timeFrame: Day 1 to Day 4
measure: Proportion of patients with Late Clinical Failure (LCF)
timeFrame: Day 5 to Day 43
measure: Proportion of patients with Late Parasitological Failure (LPF)
timeFrame: Day 8 to Day 43
measure: Incidence rate of recrudescence and reinfection
timeFrame: Day 15, Day 29 and Day 43
measure: Number of Participants with On-Treatments Adverse Events, Serious Adverse Events, and Deaths
timeFrame: Day 1 to Day 43
measure: Pharmacokinetics of KAF156 and LUM-SDF PK (Run-in Cohort, Cohort 1 and 2): Area Under the Plasma Concentration-time Curve (AUC)
timeFrame: From Day 1 to Day 8
measure: Pharmacokinetic of KAF156 and LUM-SDF PK (Run-in Cohort, Cohort 1 and 2): Maximum Observed Plasma Concentration (Cmax)
timeFrame: From Day 1 to Day 8
measure: Pharmacokinetic of KAF156 and LUM-SDF PK (Run-in Cohort, Cohort 1 and 2): Time to reach the maximum concentration after drug administration (Tmax)
timeFrame: From Day 1 to Day 8
measure: Pharmacokinetics of KAF156 and LUM-SDF PK (Run-in Cohort, Cohort 1 and 2): Plasma drug concentration 168 hours post first dose administration (C168h)
timeFrame: Day 8
measure: Pharmacokinetics of LUM from Coartem arm (Cohorts 1 and 2): Maximum Observed Plasma Concentration (Cmax)
timeFrame: From Day 1 to Day 8
measure: Pharmacokinetics of LUM from Coartem arm (Cohorts 1 and 2): Plasma drug concentration 168 hours post first dose administration (C168h)
timeFrame: Day 8
Other outcomes:
Locations:
city: Banfora
country: Burkina Faso
facility: Novartis Investigative Site
city: Bobo Dioulasso
country: Burkina Faso
facility: Novartis Investigative Site
city: Ouagadougou
country: Burkina Faso
facility: Novartis Investigative Site
city: Sabou
country: Burkina Faso
facility: Novartis Investigative Site
city: Commune De La Kenya Lubumbashi
country: Congo, The Democratic Republic of the
facility: Novartis Investigative Site
state: Du Haut Katanga
city: Abidjan
country: Côte D'Ivoire
facility: Novartis Investigative Site
city: Lambarene
country: Gabon
facility: Novartis Investigative Site
city: Kati
country: Mali
facility: Novartis Investigative Site
city: Sotuba
country: Mali
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: